Final countdown: How to transition your trials under EU-CTR
Parexel's regulatory experts shared their insight how to transition trials under EU-CTR in a live webinar on April 30. Watch on-demand to find out more about:
- The processes and timescales required to meet the EU-CTR trial transition deadline of 31 January 2025
- Actions that sponsors should take for a smooth transition process and to mitigate the risk of non-compliance as a result of missing the deadline
- Key learnings, insights and tips from regulatory experts with practical experience in how to approach the transition process
- Answers to the queries raised by our audience during the Q&A session
With the deadline for transition approaching fast, we're urging sponsors to begin the transition process for their their trials now to mitigate potential delays and the risk of trials ceasing through non-compliance with EU-CTR.
Related Insights
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Related Insights
Blog
Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison
Dec 20, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023